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ABSTRACT
Background: Rapamycin has been reported to inhibit mesenchymal cell proliferation in a murine model of
pulmonary fibrosis. In the present study, we examined the effects of rapamycin on vascular remodeling includ-
ing intraluminal myofibroblast proliferation in a murine model of allergic vasculitis with eosinophil infiltration.
Methods: C57BL6 mice were sensitized with ovalbumin (OVA) and alum. The positive controls were ex-
posed to aerosolized OVA daily for 7 days. The other group of mice was administered with rapamycin (1 mg
kg) intraperitoneally, in parallel with daily exposure to aerosolized OVA for 7 days. On the 3rd and 7th day, bron-
choalveolar lavage (BAL) was performed and the lungs were excised for pathological analysis. Cell differentials
were determined and concentrations of IL-4, IL-5, IL-13 and TGF-β in the BAL fluid (BALF) were measured.
Semi-quantitative analysis of pathological changes in the pulmonary arteries was evaluated according to the
severity of vasculitis.
Results: The number of eosinophils in BALF was reduced significantly in the mice treated with rapamycin
compared to the positive control. There was a significant decrease in the TGF-β concentration of the BALF in
the rapamycin-treated group compared to that of the positive control. The pathological scores were reduced
significantly in the rapamycin-treated group compared to the positive control group. Intraluminal myofibroblasts
in pulmonary arteries were reduced dramatically in the rapamycin-treated group compared to the positive con-
trol group.
Conclusions: Rapamycin suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis
with eosinophil infiltration through reducing eosinophil infiltration and TGF-β production in the lung and inhibi-
tion against biological action of TGF-β.
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ABBREVIATIONS
IL-4, interleukin-4; IL-5, interleukin-5; IL-13, interleukin-13; IFN-γ, interferon γ; IgE, serum immunoglobulin E;
TGF-β, transforming factor β.
INTRODUCTION
Eosinophilic granulomatous polyangitis (EGPA), a
disease of vasculitis the main lesion of which is lo-
cated in medium and small-sized vessels, is character-
ized by bronchial asthma, eosinophilia, and systemic
necrotizing vasculitis with or without granulomas.1-3
EGPA causes serious damages to the skins, nerves,
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digestive canals, lung and other organs. To date, an
effective therapy has not been established despite
many clinical trials.
The mechanism of EGPA is not completely under-
stood. Eosinophils are the most dominant cells in the
blood and extravascular tissues in EGPA, and are
known to release cytotoxic products such as major
basic protein, eosinophil-derived neurotoxin, and cy-
tokines including TGF-β.4,5
We previously reported a murine model of pulmo-
nary allergic vasculitis, which was induced by re-
peated inhalation of ovalbumin (OVA) in C57BL6
mice sensitized with OVA.6 We observed that the
small pulmonary arteries of the C57BL6 mice were
occluded with accumulated myofibroblasts and colla-
gen deposition on the 7th day.
The mammalian target of rapamycin (mTOR) is a
multifunctional protein involved in the regulation of
cell growth, proliferation, and differentiation. Rapa-
mycin is a 31-membered macrolide immunosuppres-
sant which exerts potent antiproliferative effects on
lymphoid and nonlymphoid cells by inhibiting cy-
tokine and growth-factor mediated cell signalling.7
The antiproliferative effects of rapamycine on mes-
enchymal cell growth including lung, kidney, liver etc
have been reported.8-11 Especially, the inhibition of
mTOR by rapamycin suppressed TGF-β-induced pul-
monary fibrosis by reducing collagen synthesis.12
In this regard, we examined the effects of rapamy-
cin on the histological changes in our model of aller-
gic pulmonary vasculitis. This study may contribute
to finding a therapy for allergic vasculitis.
METHODS
ANIMALS
Female C57BL6 mice (6-8 wk old) were purchased
from Japan SLC (Shizuoka, Japan). The mice were
housed under specific pathogen-free conditions fol-
lowing a 12-hour light-dark cycle and fed a standard
laboratory diet and given water ad libitum. All experi-
ments described in this study were performed ac-
cording to the guidelines for the care and use of ex-
perimental animals as determined by the Japanese
Association for Laboratory Animals Science in 1987.
ADMINISTRATION OF RAPAMYCIN
Rapamaycin (RAPACANTM1) was purchased from
Biocon (Bangalore, India). The rapamycin powder
was dissolved once in dimethyl sulfoxide (DMSO) at
2.5 mgml. Finally rapamycin was prepared at 125
μgml in a solution containing 5% polyethylene gly-
col, 5% Tween 80 and 5% DMSO in distilled water. Ra-
pamycin in the solution above was administered at 1
mgkg intraperitoneally by injection once daily dur-
ing 1 week of OVA inhalation in the rapamycin-
treated group mice. We performed preliminary ex-
periments concerning the relationship between the
doses of rapamycin (0.1-5 mgkg) and their effects on
the severity of vasculitis. In addition, taking the lethal
rate into consideration, we decided to perform the
current experiment at 1 mgkg rapamycin. In the
positive control group mice, distilled water containing
5% polyethylene glycol, 5% Tween 80 and 5% DMSO
without rapamycin was injected intraperitoneally
once daily during 1 week of OVA inhalation.
IMMUNIZATION AND AEROSOLIZATION PRO-
TOCOL
The mice were sensitized according to the methods
described in a previous paper.13 In brief, mice were
sensitized at days 0 and 5 of the protocol by an intrap-
eritoneal injection of 0.5 ml aluminum hydroxide-
precipitated antigen containing 8 μg OVA (Sigma
Chemical, St. Louis, MO, USA) adsorbed overnight at
4℃ to 4 mg of aluminium hydroxide (Wako Chemi-
cal, Tokyo, Japan) in phosphate-buffered saline
(PBS). 12 days after the second immunization, mice
were divided into 2 groups consisting of 12 animals
each. Each mouse of the positive control group was
placed in a plastic chamber (10 cm × 15 cm × 25 cm)
and exposed to aerosolized OVA (5 mgml in 0.9% sa-
line) for 1 h daily until the 7th day as shown in Figure
1. The aerosolized OVA was produced by a Pulmo-
Aide CompressorNebulizer (Devilbiss) (Sunrise
Medical HHG, Inc. Somerset, PA, USA) at a flow rate
of 5-7 litermin. The rapamycin-treated group of mice
were exposed to aerosolized OVA for 1 h daily until
the 7th day and in parallel, administered rapamycin as
described above (Fig. 1).
COLLECTION AND MEASUREMENT OF SPECI-
MENS
After being exposed to aerosolized OVA every day
over one week, the mice were killed by cutting the
femoral artery on the 3rd and 7th day, 24 hours after
the final inhalation, and blood, BALF and lung tissue
were collected as shown in Figure 1. As a control, af-
ter being exposed to aerosolized saline instead of
OVA every day over one week, samples were col-
lected. To collect BALF, the lungs were dissected and
the trachea was cannulated with a polyethylene tube
(Becton Dickinson, Sparks, MD, USA). The lungs
were lavaged twice with 0.5 ml PBS, and -0.8 ml of the
instilled fluid was consistently recovered. The recov-
ered fluid was centrifuged (300 × g for 6 min) and the
cells were resuspended in 0.5 ml PBS. The total num-
ber of cells was counted using an improved Neubauer
hemocytometer chamber. An air-dried slide prepara-
tion was made of each sample containing 10,000 cells
by cytospin (Cytocentrifuge, Sakura Seiki, Tokyo, Ja-
pan) and stained with May-Grunwald-Giemsa stain.
Differential counts of at least 500 cells were made ac-
cording to standard morphologic criteria. The num-
bers of cells recovered per mouse were then ex-
pressed as the mean and standard deviation (SD) for
each treatment group.
Effects of Rapamycin on Allergic Vasculitis
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Fig.　1　Experimental protocol. Mice were sensitized at days 0 and 5 of the protocol by an 
intraperitoneal injection of 0.5 ml aluminum hydroxide-precipitated antigen containing 8 μg 
OVA. Mice were exposed daily to the aerosolized OVA produced by a Pulmo-Aide Com-
pressor /Nebulizer at a fl ow rate of 5-7 liter/min in the plastic chamber as described in 
“Methods”. Rapamycin was administered as 1 mg/kg intraperitoneally by injection once 
daily during 1 week as described in “Methods”.
sensitization
Collection of blood, BALF and lung tissues
Rapamycin (1 mg/kg)
intraperitoneal injection
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After centrifugation, supernatants were stored at
-80°C for measurement of the cytokines. After har-
vesting the BALF, the lungs were fixed with 10% neu-
tral buffered formalin and embedded in paraffin.
These 3-μm-thick sections were stained with hema-
toxylin eosin (HE). The white blood cells and the cell
differentials in BALF were determined under micros-
copy with Giemsa staining, and the concentrations of
IL-4, IL-5, IL-13 and TGF-β in BALF were measured.
IMMUNOHISTOCHEMICAL STAINING FOR
TGF-β, α SMOOTH MUSCLE ACTIN AND Ki-67
We adopted the biotin-streptavidin system using a
Histofine Kit (Nichirei, Tokyo, Japan) for the immu-
nohistochemical staining. The sections were deparaf-
finized and treated with 0.3% hydrogen peroxide in
methanol for 15 minutes to block endogenous peroxi-
dase activity. The sections were incubated with 10%
normal rabbit serum for 30 minutes at room tempera-
ture to block the non-specific antibody reaction. We
used anti-TGF-β1 (Novus Biologicals, Littleton, CO,
USA), anti-α smooth muscle actin (α-SMA) (Spring
Bioscience, Fremont, CA, USA) and anti-mouse Ki-67
(Biolegend, San Diego, CA, USA). The sections were
incubated 60 min at room temperature with 1 : 50 fold
antibody followed by the biotin-streptavidine system,
then, 3’3-diaminobenzidine (DAB) was used as the
chromogenic substrate.
SEMI-QUANTITATIVE ANALYSIS OF PATHO-
LOGICAL CHANGES IN THE PULMONARY AR-
TERIES
The extent of histological changes in pulmonary ar-
teries was assessed as described previously.6 In brief,
the tissue was cut into sections 3 μm thick, stained
with hematoxylin-eosin and evaluated by light micros-
copy. Histological scores were determined according
to the following criteria: 0 = no abnormality; 1 = mini-
mum, 2 = mild: shedding of endothelial cells, no
change of the vascular smooth muscle layer and mild
perivascular cell infiltration were observed; 3 = mod-
erate: shedding of endothelial cells, thickening of the
vascular smooth muscle layer and moderate perivas-
cular cell infiltration were observed; and 4 = severe:
disruption of internal elastic laminae, proliferation of
mesenchymal cells in the intraluminal space in pul-
monary arteries, and moderate to severe perivascular
cell infiltration. The severity was judged by the extent
of endothelial injury, vascular smooth muscle cell
proliferation, loss of vascular wall integrity and peri-
vascular cell infiltration. We scored 5 vessels whose
diameters ranged from 20 to 50 μm in each of the
lung tissue sections and its average was determined
as the histological index of one mouse.
COUNTING Ki-67 POSITIVE CELLS
Ki-67 positive cells, those with brown-colored nuclei,
were counted under microscopy. Intraluminally accu-
mulated cells in the pulmonary arteries were
counted. The ratio of Ki-67 positive cells was calcu-
lated as the number of brown nucleinumber of
whole cells stained with hematoxylin (blue nuclei) in
the five arteries of each mouse.
CYTOKINE MEASUREMENT
BALF was used for the measurement of IL-4, IL-5,
IFN-γ and TGF-β1 concentration using a commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems, Minneapolis, MN, USA).
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Fig.　2A　The effect of rapamycin on total white blood cell 
counts in peripheral blood. Open circles: OVA-sensitized 
mice with exposure to OVA (positive control), Closed circles: 
OVA-sensitized mice with exposure to OVA and treated with 
rapamycin as described in “Methods”. Samples on the 0 day 
were collected before OVA exposure. Samples on 3rd and 7th 
day were collected after OVA exposure. Data are means ± 
SD. *p < 0.01.
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Fig.　2B　The effect of rapamycin on eosinophil counts in 
peripheral blood. Open circles: OVA-sensitized mice with ex-
posure to OVA (positive control), Closed circles: OVA-sensi-
tized mice with exposure to OVA and treated with rapamycin.
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MEASUREMENT OF IgE
The IgE levels in serum were determined with a com-
mercially available enzyme-linkedimmunosorbent as-
say (ELISA) kit (Yamasa, Chiba, Japan).
STATISTICAL ANALYSIS
Mann-Whitney U Test was used in the analysis of re-
sults. All values are expressed as means ± SD. Values
of p < 0.05 were considered statistically significant.
RESULTS
EFFECTS OF RAPAMYCIN ON CELL NUMBERS
IN PERIPHERAL BLOOD AND IN BALF
After repetitive exposure to OVA, the total white
blood cell number in peripheral blood increased to
2.6-fold of the control level on the 3rd day in the posi-
tive control mice (Fig. 2A). In contrast, the total white
blood cell numbers in the rapamycin-treated mice
were significantly lower on the 3rd and 7th day than
those in the positive control (Fig. 2A). The blood
eosinophil counts in the positive control increased af-
ter OVA inhalation. The blood eosinophil counts in
the rapamycin-treated mice were significantly lower
on the 3rd and 7th day than those in the positive con-
trol (Fig. 2B). The total cell number and the number
of eosinophils in BALF on the 3rd day increased
markedly compared with those before OVA inhala-
tion. The number of eosinophils in BALF on the 3rd
day was decreased significantly in the rapamycin-
treated mice compared with those in control positive
mice. The number of eosinophils in BALF in the
rapamycin-treated group on the 7th day also de-
creased significantly compared to that in the positive
control group (Fig. 3). In contrast, the numbers of al-
veolar macrophages in BALF in the rapamycin-
treated group increased significantly compared to
that in the positive control group.
CYTOKINE CONCENTRATION IN BALF
We measured the concentrations of IL-4, IL-5, IL-13,
IFN-γ and TGF-β in BALF on the 3rd and 7th day in
the positive control group mice and in the rapamycin-
treated group mice as described in Methods. As
shown in Figure 4A, B, C respectively, concentrations
of IL-4, IL-5 and IL-13 in BALF of the positive control
peaked on the 3rd day during 7 days and these con-
centrations in the BALF of the rapamycin-treated
group mice were decreased significantly compared
with those in the positive control. Among these cy-
tokines, the IL-4 concentration in BALF on the 7th day
was rather higher in the rapamycin-treated group
compared with the positive control. IFN-γ concentra-
tion in BALF increased on the 3rd day after OVA inha-
lation in both the positive control mice and the
rapamycin-treated mice. The IFN-γ concentrations in
BALF on the 3rd day and 7th day were not signifi-
cantly different between these two groups (Fig. 4D).
The concentrations of TGF-β in the BALF of the posi-
tive control group increased until the 7th day after
OVA inhalation and the concentrations of TGF-β in
BALF of the rapamycin-treated group decreased sig-
nificantly on the 7th day compared with those of the
positive control (Fig. 4E).
IgE CONCENTRATION IN SERUM
The IgE concentrations in serum increased on the 3rd
and 7th day after OVA inhalation in both the positive
control mice and the rapamycin-treated mice. The
IgE concentrations in serum on the 7th day were sig-
nificantly lower in rapamycin-treated mice compared
to the positive control mice (Fig. 4F).
Effects of Rapamycin on Allergic Vasculitis
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Fig.　3　The effect of rapamycin on cell differentials in BALF. Hatched columns: OVA-sen-
sitized mice (n = 6) with exposure to saline (control).  Open columns: OVA-sensitized mice 
(n = 6) with exposure to OVA (positive control). Closed columns: OVA-sensitized mice (n = 
6) with exposure to OVA and treated with rapamycin. T, total cells; A, alveolar macro-
phages; L, lymphocytes; E, eosinophils; N, neutrophils. Data are means ± SD. *p < 0.05, 
**p < 0.01.
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Fig.　4　Cytokine concentration in BALF and IgE concentration in serum Concentrations of IL-4, IL-5, IL-13, INF-γ and 
TGF-β in BALF, and IgE concentration in serum were expressed. A, IL-4; B, IL-5; C, IL-13; D, INF-γ; E, TGF-β; F, IgE. 
Open circles: OVA-sensitized mice with exposure to OVA (positive control). Closed circles: OVA-sensitized mice with 
exposure to OVA and treated with rapamycin. Data are means ± SD. *p < 0.01.
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EFFECTS OF RAPAMYCIN ON THE HISTOLOGI-
CAL CHANGES IN PULMONARY ARTERIES
In the positive control group mice, almost all small
pulmonary arteries were highly obstructed due to the
accumulation of cellular components (Fig. 5A, panel
a). In contrast, the histological changes of the small
pulmonary arteries in the rapamycin-treated mice
were markedly reduced (Fig. 5A, panel b). Semiquan-
titative analysis of the histological vascular changes
on the 7th day in the positive controls and the
rapamycin-treated mice was performed as described
in “Methods” according to severity index. The sever-
Koizumi R et al.
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Fig.　5A　Effects of rapamycin on allergic pulmonary vascu-
lar remodeling. a: Totally occluded pulmonary artery by intra-
luminal myofi broblasts (a yellow arrow) in the OVA-sensitized 
mice with exposure to OVA in 7th day (hematoxylin-eosin 
staining). b: Intraluminal myofi broblast accumulation was not 
observed in the OVA-sensitized mice with exposure to OVA
and treated with rapamycin in 7th day (hematoxylin-eosin
staining). Thickening of vascular smooth muscle cells in vas-
cular wall was also reduced by rapamycin treatment.
a b
Fig.　5B　Effects of rapamycin on severity of vascular 
changes. Open circles: histological scores of the OVA-sensi-
tized mice with exposure to OVA in 7th day (positive control, 
n = 6); closed circles: the OVA-sensitized mice with expo-
sure to OVA and treated with rapamycin in 7th day (n = 6). 
Data are given as mean ± SD. *p < 0.01.
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Fig.　6A　Immunostaining for α smooth muscle actin (α-
SMA). a: The intraluminal myofi broblasts in the OVA-sensi-
tized mice with exposure to OVA in 7th day were positively
stained with anti-α-SMA (a yellow arrow). Smooth muscle 
cells in vascular wall were also positive (a yellow arrow head) 
b: Intraluminal myofi broblast accumulation was not observed 
in the OVA-sensitized mice with exposure to OVA and treat-
ed with rapamycin. Only smooth muscle cells in vascular wall
were positive (a yellow arrow head).
a b
Fig.　6B　Immunostaining for Ki-67. a: Ki-67 positive cells 
were seen in the myofi broblasts accumulated intraluminal 
space of pulmonary artery in the OVA-sensitized mice with 
exposure to OVA in 7th day (a yellow arrow). b: Ki-67 positive 
cells were very few in the intraluminal space of the OVA-sen-
sitized mice with exposure to OVA and treated with rapamy-
cin on the 7th day.
a b
ity index in the rapamycin-treated group mice was
significantly reduced compared to that in the positive
controls (Fig. 5B). The histological changes were
minimal in the control group mice as previously re-
ported (data were not shown).
IMMUNOSTAINING FOR α-SMA ACTIN Ki-67
AND TGF-β1
The myofibroblasts in the intraluminal space of vas-
culitis were strongly stained with anti-α-SMA in the
positive control group mice (a yellow arrow) (Fig. 6A,
panel a). On the other hand, positive cells for α-SMA
were sparse in the intraluminal space of the pulmo-
nary artery in the rapamycin-treated group mice (Fig.
6A, panel b). The vascular smooth muscle cells were
strongly stained for α-SMA in both groups (a yellow
arrow head).
Immunohistochemistry for Ki-67 was performed to
detect proliferating cells in pulmonary vasculitis.14 Ki-
67 was expressed in intraluminal myofibroblasts (a
yellow arrow) and cells in the vascular wall in the
positive controls (Fig. 6B, panel a). In contrast, Ki-67
expressing cells were very sparse in the pulmonary
vascular tissue of the rapamycin-treated group mice
(Fig. 6B, panel b). Semi-quantitative analysis revealed
that the intraluminal Ki-67 positive cells on the 7th day
were significantly reduced in the rapamycin-treated
mice compared with those the positive control mice
(Fig. 6C).
Immunostaining for TGF-β revealed that TGF-β
was expressed in smooth muscle cells in the vascular
wall of pulmonary arteries (a yellow arrow head) and
myofibroblasts in the intraluminal space of vasculitis
(a yellow arrow) in the positive control (Fig. 6D,
Effects of Rapamycin on Allergic Vasculitis
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Fig.　6C　Effects of rapamycin on the number of Ki-67 posi-
tive cells. Open circles: intraluminal Ki-67 positive cells of the 
OVA-sensitized mice with exposure to OVA in 7th day (posi-
tive control, n = 6); closed circles: intraluminal Ki-67 positive 
cells of the OVA-sensitized mice with exposure to OVA and 
treated with rapamycin in 7th day (n = 6). Data are given as 
mean ± SD. *p < 0.01.
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Fig.　6D　Immunostaining for TGF-β. a: Myofi broblasts occu-
pied intraluminal space of pulmonary artery in the OVA-sen-
sitized mice with exposure to OVA in 7th day and were posi-
tively stained with anti-TGF-β 1 (a yellow arrow). Smooth
muscle cells in vascular wall were also positive for TGF-β (a
yellow arrow head) b: Only smooth muscle cells in vascular 
wall were positive (a yellow arrow head). Intraluminal myofi -
broblast accumulation was not observed in the OVA-sensi-
tized mice with exposure to OVA and treated with rapamycin. 
c: Eosinophils with horse shoe shaped nuclei in the vessel 
were not strongly but defi nitely brown colored (yellow ar-
rows). d: Eosinophils with horse shoe shaped nuclei in the 
perivascular space were stained brown for TGF-β (a yellow
arrow). Mononuclear cells in the perivascular space were 
also stained for TGF-β.
a b
c d
panel a). In contrast, TGF-β positive cells were only
smooth muscle cells and not detected in the intralu-
minal space in the rapamycin-treated group mice
(Fig. 6D, panel b). Mesenchymal cells such as myofi-
broblasts and smooth muscle cells were strongly
stained. On the other hand, the inflammatory cells
were weakly stained for TGF-β compared with the
mesenchymal cells. However, eosinophils with horse
shoe shaped nuclei in the vessel were not strongly
but definitely brown colorrd (yellow arrows)
(Fig. 6D, panel c). In addition, eosinophils with horse
shoe shaped nuclei in the perivascular space were
stained brown for TGF-β (a yellow arrow)
(Fig. 6D, panel d). Mononuclear cells in the perivas-
cular space were also stained for TGF-β (Fig. 6D,
panel d).
DISCUSSION
The present study demonstrated that rapamycin ame-
liorated the histological changes of vasculitis in the
pulmonary arteries of the OVA-exposed mouse model
of AGA and reduced the number of eosinophils in
BALF on the 7th day after OVA inhalation. Rapamycin
reduced the TGF-β concentration in the BALF of
OVA-sensitized mice after OVA inhalation and the
number of TGF-β positive cells in the lesions of vas-
culitis in the pulmonary arteries.
As previously reported, mTOR is a multifunctional
protein involved in the regulation of cell growth, pro-
liferation, and differentiation.
mTOR has been recognized as an essential mole-
cule for the maturation and differentiation of multiple
immune cell lineages.15 Fujitani et al. reported that
SDR 943, a rapamycin analogue (1 mgkg) sup-
pressed the eosinophil counts in BALF of BALBC
mice sensitized with OVA after a single inhalation of
OVA.16 Fredriksson et al. reported the effects of papa-
mycin on the eosinophil counts in BALF differed de-
pending on the timing of administration in an experi-
mental house dust mite (HDM)-induced asthma
model of BALBc mice.17 They demonstrated the
suppressive effects of rapamycin on eosinophil counts
in BALF of mice sensitized with HDM after HDM ex-
posure when rapamycin was administered during the
induction period of sensitization. In contrast, 6 weeks
after sensitization with HDM, rapamycin did not sup-
press but rather increased the eosinophil counts in
BALF of the sensitized mice after re-exposure to
HDM. Thus, consistent with the context-dependent
effects of rapamycin on inflammation, they suggested
that the timing of mTOR inhibition might be an im-
portant determinant of the efficacy and toxicity in
HDM-induced asthma. Furthermore, Mushaben et al.
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reported the effects of rapamycin on allergic asthma
model of mice sensitized with HDM.18 In their report,
rapamycin suppressed IgE, goblet cells and total
CD4+ T cells in the lung tissue, with no effect on the
total inflammatory cell numbers in the BALF, al-
though the IL-4 and eotaxin 1 levels were augmented.
Their murine asthma model was a similar to the
model in our study except for the murine species and
sensitizing allergen used. Total cell numbers in BALF
on the 7th day after OVA exposure were not affected
by rapamycin in our study, the same as in the report
of Mushaben et al. In addition, in our study the IL-4
concentration in BALF on the 7th day was not sup-
pressed by rapamycin and was rather higher in the
rapamycin-treated group compared with the positive
control. Mushaben et al. also reported similar results
in their murine model. These results suggested that
the effects of rapamycin were time-dependent and
that some refractory mechanism was involved in the
long-term.18 However we found a significant reduc-
tion of eosinophils in BALF on the 7th day after OVA
exposure by rapamycin treatment. We speculated
that these differences in the eosinophil counts in
BALF between the study of Mushaben et al. and ours
might be, in part, due to the difference in the aller-
gen, the way of sensitization and mouse species. In
addition, the time course of the produced cytokines
involved in eosinophilopoiesis, eosinophil recruit-
ment and eosinophil activation were thought to play
key roles in the accumulation of eosinophils in the
BALF.
IL-4, IL-5 and IL-13 are thought to play critical roles
in the eosinophilopoiesis, and chemotaxis, survival
and activation of eosinophils. Especially, the prolifera-
tion and differentiation of eosinophils are known to
be regulated by IL-5.19-25 The IFN-γ concentrations in
BALF on the 3rd and 7th day were not influenced by
the rapamycin treatment. Therefore, the decrease in
the eosinophil number in BALF was thought to be
caused mainly by the decreases in Th2 cytokines
such as IL-5 and IL-13 by rapamycin. Rapamycin
treatment reduced the IgE concentration on the 7th
day in our murine model. The reduction in the IgE
level might be involved in the suppression of vasculi-
tis by rapamycin. We studied possible Th1 and Th2
cytokines influencing the effects of rapamycin, but IL-
17 was not detected in the BALF. Since Th17 is
thought to be an important T lymphocyte involved in
allergic inflammation and vasculitis, Th17 cytokines
need to be studied in the next step.
In our experiments, the concentrations of IL-4, IL-5
and IL-13 in the BALF of the rapamycin-treated mice
on the 3rd day after OVA inhalation were markedly re-
duced compared with those of OVA-exposed mice
without rapamicin. In this regard, the decrease of
eosinophil counts in the BALF of the rapamycin-
treated mice on the 7th day after OVA inhalation was
thought to be due to the marked decrease of the con-
centrations of IL-4, IL-5 and IL-13 in the BALF on the
3rd day after OVA inhalation. These results suggested
that rapamycin might suppress the synthesis of IL-4,
IL-5 and IL-13 from CD4+ T lymphocytes sensitized
with OVA.26,27
Eosinophils have been thought to be a major
source of TGF-β in allergic airway diseases.28,29 Sev-
eral reports demonstrated that the TGF-β produced
by eosinophils played an important role in airway re-
modeling including increased synthesis and deposi-
tion of extracellular matrix proteins such as colla-
gens.30,31 In our study, the eosinophils in the pulmo-
nary vessels and perivascular space were positively
stained for TGF-β. In this regard, it was suggested
that the decreased number of eosinophils caused the
reduction of TGF-β concentration in the lung tissue
and BALF of the rapamycin-treated mice with OVA
exposure.
TGF-β has been known to be a key molecule in-
volved in tissue fibrosis including subepithelial fibro-
sis in asthma and pulmonary fibrosis.29,32,33 In our ex-
perimental model, we previously reported the
marked increase of TGF-β concentration in the BALF
of the OVA sensitized mice after OVA exposure.34
Present study demonstrated that rapamicin de-
creased TGF-β concentration in the BALF of the OVA
sensitized mice after OVA exposure. Simler NR et al.
reported rapamycin analogue suppressed bleomycin-
induced pulmonary fibrosis.35 In their reports, rapa-
mycin analogue SDZ RAD reduced collagen accumu-
lation in the lung of rats with pulmonary fibrosis.
Concerning the mechanism of collagen reduction by
mTOR inhibitor, rapamycin decreased steady-state
levels of collagen mRNA via phosphatidylinositol 3-
kinase-independent pathway.36
In this regard, we speculated the mechanism of in-
hibitory effects of rapamycin on allergic pulmonary
vasculitis as following: 1) Rapamcin suppressed pro-
duction of Th2 cytokines such as IL-4, IL-5 and IL-13
from CD4+ T lymphocytes sensitized with OVA in our
experimental murine model. 2) The reduced produc-
tion of Th2 cytokines especially IL-5 caused the de-
crease of eosinophils recruited into lung tissue. 3)
The decreased number of eosinophil in the lung of
the rapamycin-treated mice caused lower level of
TGF-β concentration compared with OVA-exposed
mice without rapamicin. 4) The vascular remodeling
including myofibroblast proliferation and ECM depo-
sition did not progress because of the reduced level
of TGF-β concentration in the lung tissue.
In addition, rapamycin inhibited TGF-β induced fi-
broblast proliferation.12
In conclusion, rapamicin attenuated vascular re-
modeling of murine model with allergic pulmonary
vasculitis by reduction of TGF-β production in the
lung and inhibition against biological action of TGF-β.
Effects of Rapamycin on Allergic Vasculitis
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